| 000 | 01210 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250516235123.0 | ||
| 264 | 0 | _c20150122 | |
| 008 | 201501s 0 0 eng d | ||
| 022 | _a1945-7197 | ||
| 024 | 7 |
_a10.1210/jc.2014-3290 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGrossmann, Mathis | |
| 245 | 0 | 0 |
_aMyostatin inhibition: a new treatment for androgen deprivation-induced sarcopenia? _h[electronic resource] |
| 260 |
_bThe Journal of clinical endocrinology and metabolism _cOct 2014 |
||
| 300 |
_a3625-8 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Research Support, Non-U.S. Gov't; Comment | ||
| 650 | 0 | 4 |
_aAndrogen Antagonists _xadverse effects |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fc Fragments _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMuscle, Skeletal _xdrug effects |
| 650 | 0 | 4 |
_aMyostatin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xadverse effects |
| 773 | 0 |
_tThe Journal of clinical endocrinology and metabolism _gvol. 99 _gno. 10 _gp. 3625-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1210/jc.2014-3290 _zAvailable from publisher's website |
| 999 |
_c24245267 _d24245267 |
||